GeoVax Labs, Inc.

NASDAQ (USD): GeoVax Labs, Inc. (GOVXW)

Last Price

0.157

Today's Change

-0.003 (1.87%)

Day's Change

0.157 - 0.16

Trading Volume

470

Overview

Market Cap

13 Million

Shares Outstanding

82 Million

Avg Volume

0

Avg Price (50 Days)

0.00

Avg Price (200 Days)

0.00

PE Ratio

0.00

EPS

0.00

Earnings Announcement

31-Mar-2023

Previous Close

0.16

Open

0.16

Day's Range

0.1569 - 0.16

Year Range

0.1569 - 0.16

Trading Volume

470

Price Change Highlight

1 Day Change

-1.94%

5 Day Change

84.59%

1 Month Change

164.59%

3 Month Change

354.78%

6 Month Change

213.80%

Ytd Change

214.43%

1 Year Change

-27.02%

3 Year Change

-87.48%

5 Year Change

-81.54%

10 Year Change

-81.54%

Max Change

-81.54%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment